Biological Variability of Soluble ST2 in Patients with Stable Chronic Heart Failure and Implications for Monitoring by Piper, Susan et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.amjcard.2016.04.017
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Piper, S., deCourcey, J., Sherwood, R., Amin-Youssef, G., & McDonagh, T. (2016). Biological Variability of
Soluble ST2 in Patients with Stable Chronic Heart Failure and Implications for Monitoring. American Journal of
Cardiology. 10.1016/j.amjcard.2016.04.017
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 01. May. 2017
Accepted Manuscript
Biological Variability of Soluble ST2 in Patients with Stable Chronic Heart Failure and
Implications for Monitoring
Susan Piper, MBBS, Julia deCourcey, Roy Sherwood, DPhil, George Amin-Youssef,
MB BCh, Theresa McDonagh, MD
PII: S0002-9149(16)30498-2
DOI: 10.1016/j.amjcard.2016.04.017
Reference: AJC 21812
To appear in: The American Journal of Cardiology
Received Date: 24 December 2015
Revised Date: 4 April 2016
Accepted Date: 6 April 2016
Please cite this article as: Piper S, deCourcey J, Sherwood R, Amin-Youssef G, McDonagh T, Biological
Variability of Soluble ST2 in Patients with Stable Chronic Heart Failure and Implications for Monitoring,
The American Journal of Cardiology (2016), doi: 10.1016/j.amjcard.2016.04.017.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
Biological Variability of Soluble ST2 in Patients with Stable Chronic 
Heart Failure and Implications for Monitoring 
 
Susan Pipera,b MBBS, Julia deCourceyb, Roy Sherwoodb DPhil, George Amin-
Youssefb MB BCh, Theresa McDonagha,b MD 
 
Corresponding Author 
Dr Susan Piper, Department of Cardiology, King’s College Hospital, Denmark 
Hill, London SE5 9RS.  
susan.piper@kcl.ac.uk 
Tel: 02032993259 Fax: 02032993489 
 
Departments and Affiliations 
aDepartment of Cardiovascular Research, King’s College London, The James 
Black Centre, 125 Coldharbour Lane, London SE5 9NU. 
bKings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 
9RS 
 
Short Title: Biological Variability of ST2 in CHF 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
Abstract 
 Soluble ST2 (sST2) is a novel biomarker implicated in myocardial 
remodelling and fibrosis. Recent studies in normal subjects have suggested 
the biological variability (BV) of sST2 is significantly lower than that of the B-
type natriuretic peptides, BNP & NTproBNP. It may, consequently, be a better 
biomarker for monitoring patients with chronic heart failure (CHF). To date, no 
published studies have examined the BV of sST2 in a heart failure population. 
Blood samples from 50 outpatients with pharmacologically optimised stable 
CHF and persistent left ventricular dysfunction (ejection fraction (EF) <40%). 
were collected at baseline, 1 hour, 1 month, 3 months and 6 months. Using 
log-transformed data, mean intra-individual coefficients of variation (CVI) and 
subsequent reference change values (RCV) were calculated for both 
NTproBNP and sST2. Results demonstrate significantly lower CVI and RCV 
for sST2 compared with NTproBNP at 1 month (12.02 (36%) vs. 36.75 
(103%)) p<0.001, 3 months (12.23 (36%) vs. 40.98 (114%)) p<0.001 and 6 
months (16.41 (47%) vs. 46.02 (128%)) p<0.001. In conclusion, the BV of 
sST2 is significantly lower than that of NTproBNP in patients with CHF. These 
results support previous indications that sST2 may be a better biomarker for 
monitoring such patients.  
 
Keywords: Heart Failure, Monitoring, Biomarkers 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
Introduction 
 sST2 is a member of the interleukin 1 (IL-1) receptor family that has 
recently been identified as a novel biomarker for cardiac remodelling and 
fibrosis. Raised concentrations are known to be predictive of mortality in 
patients with acutely decompensated heart failure (ADHF)1-3. Moreover, 
several studies have provided evidence for the prognostic role of serial 
measures of sST2 in patients with ADHF4-6. The role of sST2 in CHF is, 
however, less well defined7,8. Recently, Wu et al9,, have demonstrated that 
the RCV of sST2 in healthy volunteers to be much lower than that of BNP or 
NTproBNP, indicating it may be a better marker for serial monitoring. Despite 
such promising results, it is likely that variation amongst patients with disease 
will be greater than that in healthy individuals. To date, no studies analysing 
the BV or RCV of sST2 in CHF have been reported.  
 
Methods 
 Fifty patients with CHF, New York Heart Association (NYHA) Class I-III 
and left ventricular EF ≤40% were recruited from the heart failure clinics at 
Kings College Hospital, London. A subset of this cohort has been previously 
described10. All were on optimum tolerated heart failure medications. Target 
dose levels were defined according to current guidelines11. Main exclusion 
criteria were an acute cardiovascular admission or change in prognostically 
indicated medication within 4 weeks of recruitment, a planned cardiovascular 
admission, significant renal impairment (estimated glomerular filtration rate 
(eGFR) <20), or the inability or unwillingness to consent.  
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 Clinical review and blood sampling took place at 5 time points – 
baseline, 1 hour, 1 month, 3 months and 6 months. Reviews took place at the 
same time of day for each visit. Vital signs and NYHA class were recorded 
together with medications and details of any hospital admissions. 
 Blood samples were obtained by venepuncture after 30 minutes of 
semi-recumbent rest. Serum samples for creatinine were analysed 
immediately. After centrifugation at 3000 rpm, 2 mL aliquots of plasma were 
stored at -30oC until analysed.  
 sST2 was measured by enzyme linked immunosorbent assay (ELISA) 
(R&D Systems Europe, Ltd., Abingdon, UK). The sST2 assay contains NS0-
expressed recombinant human sST2 and has been shown to accurately 
quantitate the recombinant factor. The intra-assay precision was 5.6, 4.4 and 
4.5% and the inter-assay precision was 7.1, 5.4 and 6.3% at 5.4, 12.6 and 
20.6 µg/L respectively. The limit of detection was 0.005 µg/L. Reference 
range is 6.74 – 20.4 µg/L  
 NTproBNP was measured by two-site chemiluminescence 
immunoassay (Immulite 2000, Siemens Healthcare Diagnostics Ltd, 
Camberley, Surrey UK). The intra-assay precision was 5.4, 3.0 and 4.1% and 
the inter-assay precision was 6.4, 4.0 and 4.7% at 35.6, 1430 and 29725 ng/L 
respectively. The limit of detection was 10 ng/L. Reference range is 125 ng/L 
and 450 ng/L at age <75 and >75 respectively.  
 The total coefficient of variation (CVT) is composed of both analytic and 
biologic variation. Each patient’s 1 hour, 1 month, 3 month and 6 month CVT 
for both NTproBNP and sST2 was calculated from the standard deviation of 
the respective values at baseline and 1 hour, baseline and 1 month, baseline 
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and 3 months and baseline and 6 months. As concentrations of all biomarkers 
were not normally distributed, data was log transformed prior to analysis.  
 Analytical coefficient of variation (CVA) describes the reproducibility of 
the measurement of an analyte. Where possible, samples were analysed in a 
single series to minimise the contribution of inter-assay analytical variation.  
 CVI is the random variation that occurs around a homeostatic setting 
point in an individual. CVI was calculated according to the formula:  
CVI = (CVT2 – CVA2)1/2. 
 RCVs at a 95% confidence level were calculated from median CVI 
values according to the formula:  
RCV = Z x 21/2(CVI2 + CVA2)1/2 
where Z (the 95% confidence interval Z score) is 1.96.  
 Categorical variables are described as proportions. Continuous 
variables are described with mean and standard deviation for normally 
distributed variables and median and interquartile range (IQR) for non-
normally distributed variables. Data was log transformed prior to calculation 
for BV. Differences in 1 hour, 1 month, 3 month and 6 month CVI for 
NTproBNP and sST2 were analysed using the paired t test. SPSS v21 was 
used for all analyses. 
 The study was performed in accordance with ethical principles that 
have their origin in the Declaration of Helsinki and that are consistent with 
Good Clinical Practice. The East Midlands National Research Ethics Service 
Committee approved the study protocol. All patients were given full and 
adequate oral and written information about the nature, purpose, possible 
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risks and benefits of the study. Patients provided signed and dated informed 
consent before any study specific procedure was conducted.  
 
Results 
 Characteristics of the 50 patients enrolled in this study are shown in 
table 1. Four patients withdrew prior to completion of follow-up. Blood 
samples from 1 patient at the 1 hour time point and 1 patient at the 6 month 
time point were misplaced after arrival in the lab. Eight patients required 
hospital admission during the study period with decompensated heart failure.  
 Concentrations of NTproBNP and sST2 at each visit are detailed in 
table 2. There were no significant differences from baseline across the time 
points for either NTproBNP (1 month p=0.883, 3 months p=0.144, 6 months 
p=0.279) or sST2 (1 month p=0.958, 3 months p=0.857, 6 months p=0.752).  
 The mean intra-assay coefficient of variation was used as an estimate 
of overall CVA. Using this calculation, the CVAs for NTproBNP and sST2 were 
4.17% and 4.83% respectively. Mean CVI and corresponding RCVs for 
NTproBNP and sST2 at each time-point are shown in table 3.  
 Paired t-tests were used to examine differences in mean CVI across 
the time points. Compared with 1 hour CVI, significant variability was seen 
across all time points for NTproBNP; 1 hour to 1 month p=0.003, 1 hour to 3 
months p<0.001, and 1 hour to 6 months p=0.003. Variability for sST2 existed 
only between 1 hour and 6 months p=0.019. No significant difference was 
demonstrated between CVI for NTproBNP and sST2 at 1 hour (p=0.076). 
Significant differences were, however, observed between CVI for NTproBNP 
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and sST2 at all other points; 1 month p<0.001, 3 months p<0.001 and 6 
months p<0.001.  
 Repeated analysis following removal of the data from the eight patients 
with clinical decompensation during the study period did not result in any 
significant change to mean CVI for either NTproBNP (1 month 36.15 (RCV 
101%) vs. 36.75 (RCV 103%) (p=0.889); 3 months 41.54 (RCV 115%) vs. 
40.98 (114%) (p=0.631); 6 months 42.92 (RCV (120%) vs. 46.02 (RCV 128%) 
(p=0.610)) or sST2 (1 month 12.44 (RCV 37%) vs. 12.02 (RCV 36%) 
(p=0.968); 3 months 12.98 (38%) vs. 12.23 (RCV 36%) (p=0.492); 6 months 
13.54 (RCV 39%) vs.16.41 (RCV 47%) (p=0.281)).  
 
Discussion 
 This is the first reported study assessing and directly comparing the BV 
and RCVs of sST2 with NTproBNP in a stable CHF population. In contrast to 
NTproBNP, sST2 does not exhibit significant variation either in the short or 
long term with RCVs for sST2 ranging from 31% to 47%, compared with 52% 
to 128% for NTproBNP.  
 The implications of these results are clear, especially when taken in 
conjunction with previously reported data. Studies have shown that standard 
heart failure therapies reduce average NTproBNP and BNP by up to 50%12-16, 
whilst reductions in sST2 >50% have been shown to be indicative of 
therapeutic success of heart failure therapy17. Thus, based on the results 
obtained in this study, a reduction of 50% in NTproBNP cannot be attributed 
to a therapeutic intervention alone, as this reduction is less than the RCV. In 
contrast, the same changes in sST2 would be above that of the observed 
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RCV and thus more likely due to clinical intervention than variability alone. 
sST2 may therefore be better than NTproBNP for serial monitoring to guide 
therapy.  
 Questions remain, however, as to the exact pathophysiological process 
such changes in sST2 represent. Although there is much evidence to support 
its use as a marker of fibrosis, studies also indicate that it plays a vital role in 
immune modulation and inflammatory responses18-20. In the shorter-term, 
changes in sST2 may therefore reflect other underlying processes associated 
with decompensation - such as infection and renal dysfunction. Like CHF, 
chronic kidney disease (CKD) is a multifactorial disorder, occurring in the 
context of chronic co-morbid conditions, many of which are related to 
inflammation and inflammatory responses. sST2 has previously been shown 
to be associated with disease severity in CKD21 and variations in renal 
function across the time points measured could arguably influence the 
observed BV.. This study was insufficiently powered to account for such 
variables but, repeated calculations performed after the removal of any 
patients exhibiting a >25% change in creatinine did not result in a significant 
change in median CVI or RCV (data not shown).  
 Several issues including pre-analytic factors, analytical variability and 
biological variability all contribute to total variability. In order to minimise pre-
analytic factors we adopted strict entry criteria in order to establish stability at 
baseline. This is reflected by the low median values that, in the case of sST2, 
did not exceed the normal reference range. In addition, patient preparation 
and blood collection protocol was standardised across the group. Blood 
samples were stored and assays performed in the minimum number of 
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batches in order to reduce analytical variability. Although we collected only 
single samples at each time point, clinical chemistry practice has suggested 
that although duplicate samples result in a reduction of CVA, this will result in 
double the cost of reagents and is only useful if the CVA is >50% of the CVI. 
Under these conditions, it is estimated that the assay imprecision will add only 
10% to the BV. In our study the CVA of sST2 was 48% of CVI at 1 hour, 40% 
at 1 month, 39% at 3 months and 29% at 6 months. For NTproBNP CVA was 
23% of CVI at 1 hour, 11% at 1 month, 10% at 3 months and 9% at 6 months.  
 Currently there are 3 commercially available assays to sST2; the MBL 
assay, the Presage assay and the R&D assay. Whilst the majority of studies 
looking at ADHF have employed the Presage assay, studies looking at sST2 
in CHF have used a variety of all 3. Mueller et al22 performed a comparison of 
plasma concentrations by these assays and found considerable differences 
between concentrations obtained. Results between the methods are, 
therefore, not directly comparable. They were not, however, able to 
demonstrate any superiority of any assay over another. Although such 
differences will impart changes to the CVA, CVI should be consistent 
regardless of the assay utilised. To date, there are no comparative studies 
assessing the BV of sST2 in CHF, however previous studies looking at the 
natriuretic peptides demonstrated similar BV and RCV across both healthy 
individuals and those with CHF. In support of our findings, Wu et al9 recently 
examined the BV of sST2 in healthy individuals, using the Presage assay. In 
this they demonstrate a CVI of 11% and RCV of 30% for sST2 at 2 months. 
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Age (years) mean (SD; Range) 
 
67.3 (11.6; 45-87) 
Men n=41 (82%) 
Body mass index (kg/m2) mean (SD; 
Range) 
 
30 (5.7; 20-45) 
Hypertension n=25 (50%) 
Diabetes Mellitus n=8 (16%) 
Coronary heart disease n=24 (48%) 
Atrial fibrillation n=12 (24%) 
QRS (ms) mean (SD; Range) 
 
130.4 (38.4; 75-222) 
Cardiac Resynchronisation Therapy n=14 (28%) 
Implantable Cardiac Defibrillator n=7 (14%) 
New York Heart Association Class I n=5 (10%) 
New York Heart Association Class II n=35 (70%) 
New York Heart Association Class III n=10 (20%) 
Estimated Glomerular Filtration Rate 
mean (SD; Range) 
 
64.2 (17.9; 26-91) 
Medication  
Angiotensin Converting Enzyme Inhibitor n=37 (74%) 
Angiotensin Receptor Blocker n=13 (26%) 
Beta-blocker n=45 (90%) 
Mineralocorticoid Receptor Antagonist n=34 (68%) 
Digoxin n=8 (16%) 
Regular Loop Diuretics n=37 (74%) 
Echo  
Ejection Fraction mean (SD; Range) 30.7 (6.7; 14-40) 
Moderate-Severe Valve disease n=12 (24%) 
Table 1: Baseline patient characteristics 
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 Baseline 
 
One Month 
 
Three Months 
 
Six Months 
NTproBNP 
(µg/L) 
300 
(80.8-1282) 
466 
(80.2-1171) 
291 
(46.5-1006) 
356 
(61.9-1469) 
sST2 
(µg/L) 
17.6 
(13.3-22.5) 
17.3 
(13.6-21.5) 
17.1 
(13.8-22.5) 
16.9 
(13.7-21.6) 
Table 2: Median (IQR) biomarker concentrations at each time point 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 One Hour One Month Three Months Six Months 
NTproBNP sST2 NTproBNP sST2 NTproBNP sST2 NTproBNP sST2 
Mean 
CVi 
18.47 9.99 36.75 12.02 40.98 12.23 46.02 16.41 
RCV 
(%) 
52 31 103 36 114 36 128 47 
Table 3: Mean CVI and corresponding RCV at each time point 
 
